Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder
- 10 June 2005
- journal article
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 3 (2), 73-80
- https://doi.org/10.1111/j.1476-5810.2005.00070.x
Abstract
Invasive transitional cell carcinoma (TCC) of the urinary bladder responds poorly to medical therapy. Combining platinum chemotherapy with a cyclooxygenase (cox) inhibitor has shown promise against canine TCC, where the disease closely mimics the human condition. A phase II clinical trial of carboplatin combined with the cox inhibitor, piroxicam, was performed in 31 dogs with naturally occurring, histopathologically confirmed, measurable TCC. Complete tumour staging was performed before and at 6‐week intervals during therapy. Tumour responses in 29 dogs included 11 partial remissions, 13 stable disease and five progressive disease. Two of the 31 dogs were withdrawn prior to the re‐staging of the tumour. Gastrointestinal toxicity was observed in 23 dogs. Hematologic toxicity was noted in 11 dogs. The median survival was 161 days from first carboplatin treatment to death. In conclusion, carboplatin/piroxicam induced remission in 40% of dogs providing evidence that a cox inhibitor enhances the antitumour activity of carboplatin. The frequent toxicity and limited survival, however, do not support the use of this specific protocol against TCC.Keywords
This publication has 21 references indexed in Scilit:
- Withdrawal of Vioxx Casts a Shadow Over COX-2 InhibitorsScience, 2004
- Systemic chemotherapy for patients with bladder cancer – current controversies and future directionsCancer Treatment Reviews, 2004
- Resveratrol is a Peroxidase-mediated Inactivator of COX-1 but Not COX-2Journal of Biological Chemistry, 2004
- ADJUVANT CHEMOTHERAPY WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED BLADDER CANCER: A STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUPJournal of Urology, 2004
- Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?Drug Safety, 2004
- Expression of Cyclooxygenase-2 in Human Transitional Cell Carcinoma of the Urinary BladderThe American Journal of Pathology, 2001
- Piroxicam Therapy in 34 Dogs With Transitional Cell Carcinoma of the Urinary BladderJournal of Veterinary Internal Medicine, 1994
- Renal complications of nonsteroidal anti-inflammatory drugsKidney International, 1993
- Cisplatin nephrotoxicityCancer Chemotherapy and Pharmacology, 1989